150 related articles for article (PubMed ID: 19817696)
1. MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
Kanteti R; Yala S; Ferguson MK; Salgia R
J Environ Pathol Toxicol Oncol; 2009; 28(2):89-98. PubMed ID: 19817696
[TBL] [Abstract][Full Text] [Related]
2. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.
Tanaka A; Sueoka-Aragane N; Nakamura T; Takeda Y; Mitsuoka M; Yamasaki F; Hayashi S; Sueoka E; Kimura S
Lung Cancer; 2012 Jan; 75(1):89-94. PubMed ID: 21733594
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
4. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
5. Large fragment Bst DNA polymerase for whole genome amplification of DNA from formalin-fixed paraffin-embedded tissues.
Aviel-Ronen S; Qi Zhu C; Coe BP; Liu N; Watson SK; Lam WL; Tsao MS
BMC Genomics; 2006 Dec; 7():312. PubMed ID: 17156491
[TBL] [Abstract][Full Text] [Related]
6. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
Tan YH; Krishnaswamy S; Nandi S; Kanteti R; Vora S; Onel K; Hasina R; Lo FY; El-Hashani E; Cervantes G; Robinson M; Hsu HS; Kales SC; Lipkowitz S; Karrison T; Sattler M; Vokes EE; Wang YC; Salgia R
PLoS One; 2010 Jan; 5(1):e8972. PubMed ID: 20126411
[TBL] [Abstract][Full Text] [Related]
7. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
8. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features and prognostic implications of EGFR/c-Met gene copy number and protein expression in non-small cell lung cancer].
Ai T; Wang N; Li WW; Song LP
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):825-9. PubMed ID: 21223687
[TBL] [Abstract][Full Text] [Related]
10. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.
Ach T; Zeitler K; Schwarz-Furlan S; Baader K; Agaimy A; Rohrmeier C; Zenk J; Gosau M; Reichert TE; Brockhoff G; Ettl T
Virchows Arch; 2013 Jan; 462(1):65-72. PubMed ID: 23242174
[TBL] [Abstract][Full Text] [Related]
11. No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer.
Pallier K; Houllier AM; Le Corre D; Cazes A; Laurent-Puig P; Blons H
Mol Carcinog; 2009 Jul; 48(7):581-5. PubMed ID: 19353596
[TBL] [Abstract][Full Text] [Related]
12. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
[TBL] [Abstract][Full Text] [Related]
13. Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand.
Saiyaros K; Kritpetcharat P; Pairojkul C; Sithithaworn J
Asian Pac J Cancer Prev; 2019 May; 20(5):1339-1343. PubMed ID: 31127887
[TBL] [Abstract][Full Text] [Related]
14. An improved method for semiquantification of gene amplification from archival material.
Underwood MA; Bartlett JM; Cooke TG
PCR Methods Appl; 1994 Dec; 4(3):178-84. PubMed ID: 7580903
[TBL] [Abstract][Full Text] [Related]
15. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
[TBL] [Abstract][Full Text] [Related]
16. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
17. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
[TBL] [Abstract][Full Text] [Related]
18. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
19. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
[TBL] [Abstract][Full Text] [Related]
20. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
